CVS Health Corporation(CVS)Earnings, Financials & Key RatiosCVS Health Corporation (CVS) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the forward P/E of 14.06 suggests potential value, the high goodwill balance of $85.5B and volatile earnings history warrant a cautious approach.
CVS Health Corporation (CVS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
CVS Health Corporation (CVS) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $2.57vs $2.18+17.9% | $100.4Bvs $95.0B+5.7% |
| Q1 2026 | Feb 10, 2026 | $1.09vs $1.00+9.0% | $105.7Bvs $103.7B+1.9% |
| Q4 2025 | Oct 29, 2025 | $1.60vs $1.37+16.8% | $102.9Bvs $98.8B+4.1% |
| Q3 2025 | Jul 31, 2025 | $1.81vs $1.46+24.0% | $98.9Bvs $94.5B+4.6% |
Recent stock market news and headlines for CVS Health Corporation (CVS)
The Pacer US Cash Cows 100 ETF (CBOE: COWZ) is having a solid 2026, up 6.4% year to date and 14.81% over the past year through July 6. Yet a fund built expressly to own America's biggest cash machines holds zero shares of Apple, arguably the most famous cash generator on the planet. That contradiction is... Up 14.81% in a Year, COWZ Proves You Don't Need Apple
Does CVS Health (CVS) have what it takes to be a top stock pick for momentum investors? Let's find out.
WOONSOCKET, R.I., July 6, 2026 /PRNewswire/ -- CVS Health® (NYSE: CVS) will hold a conference call with analysts and investors on Wednesday, August 5, 2026, at 8:00 a.m.
CVS Health Corporation has outperformed peers, overcoming industry headwinds through effective management and strategic execution. CVS delivered a Q1 beat-and-raise, expects margin expansion in 2026, and projects low-double-digit investor returns. While Health Services and Insurance segments anticipate mid-single-digit growth, retail is set for gradual decline but with margin improvements.
UnitedHealth generates higher overall revenue, though CVS Health has occasionally narrowed the gap between the two companies. Both companies experienced steady quarter-over-quarter revenue expansion through late 2025 before posting slight sequential declines in early 2026.
Key metrics vs top competitors for CVS Health Corporation (CVS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $104.33 | $133.12B | 75.06 | 7.85% | 0.44% | 2.34% | 2.56% | |
| $428.19 | $388.86B | 32.37 | 11.81% | 2.68% | 11.54% | — | |
| $286.62 | $75.57B | 12.93 | 11.26% | 2.26% | 15.08% | — | |
| $418.85 | $90.96B | 16.67 | 12.62% | 2.62% | 11.92% | — | |
| $394.62 | $47.38B | 40.10 | 10.06% | 0.82% | 6.17% | — | |
| $807.33 | $97.04B | 21.04 | 12.36% | 1.18% | — | — |
CVS Health Corporation (CVS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CVS Health Corporation (CVS) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 6, 2026·SEC
Mar 19, 2026·SEC
Feb 10, 2026·SEC
Get notified when CVS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CVS Health Corporation (CVS) stock FAQ — growth, dividends, profitability & financials explained
CVS Health Corporation (CVS) reported $407.90B in revenue for fiscal year 2025. This represents a 3348% increase from $11.83B in 1996.
CVS Health Corporation (CVS) grew revenue by 7.8% over the past year. This is steady growth.
Yes, CVS Health Corporation (CVS) is profitable, generating $2.93B in net income for fiscal year 2025 (0.4% net margin).
Yes, CVS Health Corporation (CVS) pays a dividend with a yield of 2.56%. This makes it attractive for income-focused investors.
CVS Health Corporation (CVS) has a return on equity (ROE) of 2.3%. This is below average, suggesting room for improvement.
CVS Health Corporation (CVS) generated $7.39B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
